Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.37 |
| ▸ | PRKCG | P05129 | 1/20 | 0.37 |
| ▸ | PRKCB | P05771 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.33 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135802 | 1.00 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670631 | 1.00 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670633 | 1.00 | PRKCA (0.37) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL29678404 | 0.90 | PRKCA (0.36) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670654 | 0.86 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670630 | 0.86 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670648 | 0.85 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670646 | 0.85 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL23409157 | 0.84 | HPGD (0.39) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL20658024 | 0.82 | PRKCG (0.33) | PRKCAPRKCGPRKCBPRKCEPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4499106-A2 | NUCLEOSIDE LINE-1 INHIBITORS | Transposon Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | PRKCA 4741/4885PRKCG 4745/4885PRKCB 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.